Advertisement

Journal of Materials Science

, Volume 49, Issue 23, pp 8140–8153 | Cite as

Fabrication of cyclodextrin nanosponges for quercetin delivery: physicochemical characterization, photostability, and antioxidant effects

  • Singireddy Anandam
  • Subramanian Selvamuthukumar
Original Paper

Abstract

Quercetin is a flavonoid widely distributed in vegetables and fruits and exhibits strong antioxidant activity, but the poor solubility and stability of quercetin limit its function and application. The purpose of this study was to enhance the dissolution rate and stability of a poorly water-soluble drug quercetin by complexation with cyclodextrin-based nanosponges. Nanosponges are recently developed sponge-like structures and have the capacity to interact with small molecules in its matrix. In this study, five types of nanosponges were purposely designed by varying the molar ratio of β-cyclodextrin and diphenyl carbonate. Quercetin was loaded into nanosponges by freeze-drying method. The particle sizes of plain and quercetin-loaded nanosponges are in between 40 and 100 nm with low polydispersity indices. Zeta potential is sufficiently high to obtain a stable colloidal nanosuspension. Fourier transformed infrared, Raman spectroscopy, differential scanning calorimetry, and X-ray powder diffraction studies confirmed the interaction of quercetin with nanosponges. Particle sizes measured from TEM images were in agreement with DLS results. The dissolution of the quercetin nanosponges was significantly higher compared with the pure drug. The stability of encapsulated quercetin nanosponge was tracked in a simulated intestinal fluid. A marked improvement in the photostability was also observed. In addition, the antioxidant activity of the quercetin nanosponges was more effective than pure quercetin on DPPH scavenging, anti-superoxide formation, and superoxide anion scavenging. These results signify that nanosponge formulations can be used as effective nanocarriers for the delivery of quercetin.

Keywords

Quercetin DPPH Cyclodextrin Inclusion Complex Solid Lipid Nanoparticles 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

We would like to thank Prof. K. Venu Gopal Reddy (Director, Central Facilities for Research and Development, Osmania University, Hyderabad) for assistance with FTIR analysis and Mr. Rajender (Centre for Nano Science & Technology, Jawaharlal Nehru Technological University, Hyderabad) for technical support with the XRD and TEM. We are very much grateful to UGC-SAP-DRS–PHASE I, New Delhi, India for providing financial assistance to carry out this work.

References

  1. 1.
    Dias K, Nikolaou S, De Giovani WF (2008) Synthesis and spectral investigation of Al(III) catechin/β-cyclodextrin and Al(III) quercetin/β-cyclodextrin inclusion compounds. Spectrochim Acta A Mol Biomol Spectrosc 70:154–161CrossRefGoogle Scholar
  2. 2.
    Hollman PC, Katan MB (1999) Dietary flavonoids: intake, health effects and bioavailability. Food Chem Toxicol 37:937–942CrossRefGoogle Scholar
  3. 3.
    Scambia G, Ranelletti FO, Panici PB et al (1990) Inhibitory effect of quercetin on OVCA 433 cells and presence of type II oestrogen binding sites in primary ovarian tumors and cultured cells. Br J Cancer 62:942–946CrossRefGoogle Scholar
  4. 4.
    Scambia G, Ranelletti FO, Benedetti Panici P et al (1992) Inhibitory effect of quercetin on primary ovarian and endometrial cancers and synergistic activity with cis-diamminedichloroplatinum (II). Gynecol Oncol 45:13–19CrossRefGoogle Scholar
  5. 5.
    Li H, Zhao X, Ma Y, Zhai G, Li L, Lou H (2009) Enhancement of gastrointestinal absorption of quercetin by solid lipid nanoparticles. J Control Release 133:238–244CrossRefGoogle Scholar
  6. 6.
    Ross JA, Kasum CM (2002) Dietary flavonoids: bioavailability, metabolic effects, and safety. Annu Rev Nutr 22:19–34CrossRefGoogle Scholar
  7. 7.
    Gregory S, Kelly ND (2001) Quercetin. Altern Med Rev 16:172–194Google Scholar
  8. 8.
    Chen-yu G, Chun-fen Y, Qi-lu L et al (2012) Development of a quercetin-loaded nanostructured lipid carrier formulation for topical delivery. Int J Pharm 430:292–298CrossRefGoogle Scholar
  9. 9.
    Kumari A, Yadav SK, Pakade YB, Singh B, Yadav SC (2010) Development of biodegradable nanoparticles for delivery of quercetin. Colloids Surf B Biointerfaces 80:184–192CrossRefGoogle Scholar
  10. 10.
    Wang Q, Bao Y, Ahire J, Chao Y (2013) Co-encapsulation of biodegradable nanoparticles with silicon quantum dots and quercetin for monitored delivery. Adv Healthc Mater 2:459–466CrossRefGoogle Scholar
  11. 11.
    Ader P, Wessmann A, Wolffram S (2000) Bioavailability and metabolism of the flavonol quercetin in the pig. Free Radic Biol Med 28:1056–1067CrossRefGoogle Scholar
  12. 12.
    Mulholland PJ, Ferry DR, Anderson D et al (2001) Pre-clinical and clinical study of QC12, a water-soluble, pro-drug of quercetin. Ann Oncol 12:245–248CrossRefGoogle Scholar
  13. 13.
    Zhang Y, Pan Y, Wang J, Zhang L, Long B, Lıu X (2006) Study on distribution of liposome nanoparticles loaded quercetin in mice. Nanoscience 11:89–94Google Scholar
  14. 14.
    Wang G, Wang JJ, Yang GY et al (2012) Effects of quercetin nanoliposomes on C6 glioma cells through induction of type III programmed cell death. Int J Nanomed 7:271–280CrossRefGoogle Scholar
  15. 15.
    Wu TH, Yen FL, Lin LT, Tsai TR, Lin CC, Cham TM (2008) Preparation, physicochemical characterization, and antioxidant effects of quercetin nanoparticles. Int J Pharm 346:160–168CrossRefGoogle Scholar
  16. 16.
    Li H, Zhao X, Ma Y, Zhai G, Li L, Lou H (2009) Enhancement of gastrointestinal absorption of quercetin by solid lipid nanoparticles. J Control Release 133:238–244CrossRefGoogle Scholar
  17. 17.
    Dhawan S, Kapil R, Singh B (2011) Formulation development and systematic optimization of solid lipid nanoparticles of quercetin for improved brain delivery. J Pharm Pharmacol 63:342–351CrossRefGoogle Scholar
  18. 18.
    Sahoo NG, Kakran M, Shaal LA et al (2011) Preparation and characterization of quercetin nanocrystals. J Pharm Sci 100:2379–2390CrossRefGoogle Scholar
  19. 19.
    Fang R, Hao R, Wu X, Li Q, Leng X, Jing H (2011) Bovine serum albumin nanoparticle promotes the stability of quercetin in simulated intestinal fluid. J Agric Food Chem 59:6292–6298CrossRefGoogle Scholar
  20. 20.
    Tan Q, Liu W, Guo C, Zhai G (2011) Preparation and evaluation of quercetin-loaded lecithin-chitosan nanoparticles for topical delivery. Int J Nanomed 6:1621–1630CrossRefGoogle Scholar
  21. 21.
    Wang Q, Bao Y, Ahire J, Chao Y (2013) Co-encapsulation of biodegradable nanoparticles with silicon quantum dots and quercetin for monitored delivery. Adv Healthc Mater 2:459–466CrossRefGoogle Scholar
  22. 22.
    Manuela C, Giuseppe C, Ortensia IP, Francesca I, Nevio P, Francesco P (2012) Quercetin-imprinted nanospheres as novel drug delivery devices. J Funct Biomater 3:269–282CrossRefGoogle Scholar
  23. 23.
    Deepak C, Sanjay KN, Anupama M, Mahesh C, Neeraj K (2012) Development of quercetin nanoformulation and in vivo evaluation using streptozotocin induced diabetic rat model. Drug Deliv Transl Res 2:112–123CrossRefGoogle Scholar
  24. 24.
    Pool H, Quintanar D, Figueroa JD, Mano CM, Bechara JH, Godínez LA, Mendoza S (2012) Antioxidant effects of quercetin and catechin encapsulated into PLGA nanoparticles. J Nano Mater. doi: 10.1155/2012/145380 Google Scholar
  25. 25.
    Bennet D, Marimuthu M, Kim S, An J (2012) Dual drug-loaded nanoparticles on self-integrated scaffold for controlled delivery. Int J Nanomed 7:3399–3419Google Scholar
  26. 26.
    Smita P, Manjappa AS, Ukawala M, Murthy RSR (2012) PLGA nanoparticles loaded with etoposide and quercetin dihydrate individually: in vitro cell line study to ensure advantage of combination therapy. Cancer Nanotechnol 3:25–36CrossRefGoogle Scholar
  27. 27.
    Wang BL, Gao X, Men K et al (2012) Treating acute cystitis with biodegradable micelle-encapsulated quercetin. Int J Nanomed 7:2239–2247Google Scholar
  28. 28.
    Tan BJ, Liu Y, Chang KL, Lim BK, Chiu GN (2012) Perorally active nanomicellar formulation of quercetin in the treatment of lung cancer. Int J Nanomed 7:651–661CrossRefGoogle Scholar
  29. 29.
    Zheng Y, Haworth IS, Zuo Z, Chow MS, Chow AH (2005) Physicochemical and structural characterization of quercetin-β-cyclodextrin complexes. J Pharm Sci 94:1079–1089CrossRefGoogle Scholar
  30. 30.
    Jullian C, Moyano L, Yañez C, Olea-Azar C (2007) Complexation of quercetin with three kinds of cyclodextrins: an antioxidant study. Spectrochim Acta A Mol Biomol Spectrosc 67:230–234CrossRefGoogle Scholar
  31. 31.
    Bergonzi MC, Bilia AR, Di Bari L, Mazzi G, Vincieri FF (2007) Studies on the interactions between some flavonols and cyclodextrins. Bioorg Med Chem Lett 17:5744–5748CrossRefGoogle Scholar
  32. 32.
    Zheng Y, Chow AH (2009) Production and characterization of a spray-dried hydroxypropyl-beta-cyclodextrin/quercetin complex. Drug Dev Ind Pharm 35:727–734CrossRefGoogle Scholar
  33. 33.
    Carlotti ME, Sapino S, Ugazio E, Caron G (2011) On the complexation of quercetin with methyl-β-cyclodextrin: photostability and antioxidant studies. J Incl Phenom Macrocycl Chem 70:81–90CrossRefGoogle Scholar
  34. 34.
    Challa R, Ahuja A, Ali J, Khar RK (2005) Cyclodextrins in drug delivery: an updated review. AAPS PharmSciTech 6:E329–E356CrossRefGoogle Scholar
  35. 35.
    Szejtli J (1991) Cyclodextrin in drug formulations Part I. Pharm Technol Int 3:15–22Google Scholar
  36. 36.
    Szente L, Szejtli J (1999) Highly soluble cyclodextrin derivatives: chemistry, properties, and trends in development. Adv Drug Deliv Rev 36:17–28CrossRefGoogle Scholar
  37. 37.
    Lala R, Thorat A, Gargote C (2011) Current trends in β-cyclodextrin based drug delivery systems. Int J Res Ayurveda Pharm 2:1520–1526Google Scholar
  38. 38.
    Ansari KA, Vavia PR, Trotta F, Cavalli R (2011) Cyclodextrin-based nanosponges for delivery of resveratrol: in vitro characterisation, stability, cytotoxicity and permeation study. AAPS PharmSciTech 12:279–286CrossRefGoogle Scholar
  39. 39.
    Swaminathan S, Pastero L, Serpe L et al (2010) Cyclodextrin-based nanosponges encapsulating camptothecin: physicochemical characterization, stability and cytotoxicity. Eur J Pharm Biopharm 74:193–201CrossRefGoogle Scholar
  40. 40.
    Swaminathan S, Vavia PR, Trotta F et al (2013) Structural evidence of differential forms of nanosponges of beta-cyclodextrin and its effect on solubilization of a model drug. J Incl Phenom Macrocycl Chem 76:201–211CrossRefGoogle Scholar
  41. 41.
    Selvamuthukumar S, Anandam S, Krishnamoorthy K, Rajappan M (2012) Nanosponges: a novel class of drug delivery system—review. J Pharm Pharm Sci 15:103–111Google Scholar
  42. 42.
    Teslova T, Corredor C, Livingstone R et al (2007) Raman and surface-enhanced Raman spectra of flavone and several hydroxy derivatives. J Raman Spectrosc 38:802–818CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Singireddy Anandam
    • 1
  • Subramanian Selvamuthukumar
    • 1
  1. 1.Department of Pharmacy, Faculty of Engineering and TechnologyAnnamalai UniversityAnnamalai NagarIndia

Personalised recommendations